Refine/Revise Search
Asking Price: $9,850,000

Transparent Antiviral Masks/Respirators 14 Patents

San Clemente, CA
Orange County

Our client offers a disruptive line of transparent antiviral masks and respirators that improve protection without compromising comfort, compliance, and human connectivity. Fourteen worldwide patents and patents pending protect four fully developed products and seven product lines for reusable and disposable respirators and surgical mask products. These reusable and disposable product lines include detachable protective eye shields, clip-on temple bars and detachable magnification lenses; disposable surgical masks, disposable surgical respirators, and reusable surgical respirators, (with or without protective eyewear) plus other accessories.Medical providers have long deployed surgical masks and respirators to reduce infections caused by airborne pathogens. The Covid pandemic drove masks and respirators onto the world stage. While N95 respirators and surgical masks protect wearers, professionals, and civilians, all have had to accept pragmatic problems. These deficiencies are not just nuisances, they reduce usage, compliance, and efficacy. These include oxygen deprivation, skin irritation and damage, headache reactions, ineffective filtration, ophthalmic and otolaryngologic distress. Our client’s revolutionary products will directly address each of these issues.Beyond these pragmatic issues, current product offerings are an imposing impairment to human connection. Studies have shown that patient disposition is affected by facial expression received from doctors and medical staff. A masked face is not a friendly one. Yet, we have accepted the human disruption of current commodity offerings. Our client believes a better way to protect humanity is with products that protect people without interrupting the human and social connectivity between people, at work, in life, or in healthcare when they are likely to be in a vulnerable position, individually or collectively.Our client, after having developed the R&D for its transformational line of surgical masks and respirators and given the criticality of such solutions to the marketplace, is seeking a large manufacturer and/or distributer to partner with instead of pursuing a more typical start-up path. In this case, existing products are so highly commoditized, that a significant opportunity exists for a company to leverage its manufacturing, marketing, distribution, and other assets and capabilities to seize and scale the opportunity. Our client understands that this approach likely reduces its financial pay-off. Our client wishes to sell all its intellectual assets, designs, patents, etc. to a leader (or prospective leader) that shares its vision for the industry.After the sale, the founder and developer, is willing to continue engaging with the project to continue R&D and design work if desired by the acquiring organization. He has dozens of patents and is well known in the industry.This opportunity is not yet operating and generating revenue. However, our client has developed four products which include seven product lines with or without protective eyewear. These include disposable surgical masks, disposable surgical respirators, and reusable surgical respirators, with or without protective eyewear (and other accessories). According to numerous scientific studies and consistent feedback from those in the medical field, there are many well-known issues with today’s mask offerings. Our client set out to solve these problems and has designed the best respirator and mask product lines. NDA is required to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

Cash Flow Not Disclosed
Revenue $12,000
$ Owner Financing Available

Asking Price: $1,955,000

Ambulance & Wheelchair Transportation

Not Disclosed, NE
Not disclosed

Their primary services include ambulance transportation (which makes up 80% of their services) as well as wheelchair accessible or specialty transport, event standby, and EMS education services. It is an ambulance business that has Hospital, Nursing homes, and VA contracts, serving both emergency and nonemergency calls. Their established staff includes 1 general manager, 2 division supervisors, 2 billing reps, 9 dispatchers, 13 medics, 31 EMTs, 6 drivers, and 2mechanics. This business operates out of a 20,000 square feet combined garage and dispatch center. The owner believes his responsibilities could be absorbed by their general manager as this GM has handled their responsibilities in the past. The owner has offered a transition/ training period of 1 year. The purchase includes all contracts, insurance agreements, 15 ambulances, 9 vans with medical equipment valued at $1,200,000 plus over $350,000 in AR! The buyer receives over $1.5 million in total assets for $460,000 cash down!This business is important to the community it serves, providing lifesaving services in a way that makes a huge impact in their clients’ lives. Growth opportunities for this business moving forward would include getting involved with insurance contracts to offer communityparamedic services including home visits to decrease individuals with a high rate of repeatedly needing ambulance assistance. Priced at $1,955,000, with a down payment of $460,000, a seller promissory note of $350,000 and an earn out based on performance, this business is primed to return new ownership high levels of financial and operational success.

Cash Flow Not Disclosed
Revenue $2,380,325
$ Owner Financing Available

Asking Price: $20,000,000

Patented Universal Tumor-Targeting Drug Delivery

Irvine, CA
Orange County

Patented Universal Tumor-Targeting Drug Delivery Platform Co.This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company’s ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company’s ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to 'universally' target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers.The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin.The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations.As the Company’s platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI.The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); followed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company’s valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approximately 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support.NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners.

Cash Flow Not Disclosed
Revenue Not Disclosed
$ Owner Financing Available

loading...
TOP ▲
Add Businesses and/or Franchises
To Basket For Free Information

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our cookies information for more details.